{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T05:24:57Z","timestamp":1700025897900},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Anesth\/J Can Anesth"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/bf03022259","type":"journal-article","created":{"date-parts":[[2009,5,3]],"date-time":"2009-05-03T20:24:15Z","timestamp":1241382255000},"page":"S123-S134","source":"Crossref","is-referenced-by-count":7,"title":["Diagnosis and management of heparin-induced thrombocytopenia"],"prefix":"10.1007","volume":"53","author":[{"given":"Emmanuel","family":"Maistre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Gruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Lasne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03022259_CR1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2141.2003.04334.x","volume":"121","author":"TE Warkentin","year":"2003","unstructured":"Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535\u201355.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR2","first-page":"241","volume":"8","author":"Y Gruel","year":"2002","unstructured":"Gruel Y, Pouplard C. Physiopathologie des thrombop\u00e9nies et des thromboses induites par \u013eh\u00e9parine. H\u00e9matologie 2002; 8: 241\u201352.","journal-title":"H\u00e9matologie"},{"key":"BF03022259_CR3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","volume":"68","author":"J Amiral","year":"1992","unstructured":"Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95\u20136.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1055\/s-0038-1648491","volume":"67","author":"A Greinacher","year":"1992","unstructured":"Greinacher A, Michels I, Mueller-Eckhardt C. Heparinassociated thrombocytopenia: the antibody is not hepa rin specific. Thromb Haemost 1992; 67: 545\u20139.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR5","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V83.11.3232.3232","volume":"83","author":"JG Kelton","year":"1994","unstructured":"Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232\u20139.","journal-title":"Blood"},{"key":"BF03022259_CR6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2004-04-1544","volume":"105","author":"L Rauova","year":"2005","unstructured":"Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105: 131\u20138.","journal-title":"Blood"},{"key":"BF03022259_CR7","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1161\/01.CIR.99.19.2530","volume":"99","author":"C Pouplard","year":"1999","unstructured":"Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530\u20136.","journal-title":"Circulation"},{"key":"BF03022259_CR8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","volume":"96","author":"TE Warkentin","year":"2000","unstructured":"Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703\u20138.","journal-title":"Blood"},{"key":"BF03022259_CR9","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1055\/s-0038-1649983","volume":"74","author":"JT Brandt","year":"1995","unstructured":"Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564\u201372.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR10","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood.V92.5.1526","volume":"92","author":"LE Carlsson","year":"1998","unstructured":"Carlsson LE, Santoso S, Baurichter G, et al. Heparininduced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism. Blood 1998; 92: 1526\u201331.","journal-title":"Blood"},{"key":"BF03022259_CR11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.V89.2.370","volume":"89","author":"G Arepally","year":"1997","unstructured":"Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc gamma RIIA H\/R 131 polymorphism, subclass-specific IgG anti-heparin\/platelet factor 4 antibodies and clinical course in patients with heparininduced thrombocytopenia and thrombosis. Blood 1997; 89: 370\u20135.","journal-title":"Blood"},{"key":"BF03022259_CR12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1046\/j.1365-2141.1996.407945.x","volume":"92","author":"J Amiral","year":"1996","unstructured":"Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D. Pathogenicity of IgA and\/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954\u20139.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.V88.2.410.bloodjournal882410","volume":"88","author":"J Amiral","year":"1996","unstructured":"Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996; 88: 410\u20136.","journal-title":"Blood"},{"key":"BF03022259_CR14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajcp\/111.5.700","volume":"111","author":"C Pouplard","year":"1999","unstructured":"Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700\u20136.","journal-title":"Am J Clin Pathol"},{"key":"BF03022259_CR15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1046\/j.1365-2141.1996.d01-1944.x","volume":"95","author":"DH Lee","year":"1996","unstructured":"Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996; 95: 724\u201331.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM198703053161004","volume":"316","author":"DB Cines","year":"1987","unstructured":"Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 581\u20139.","journal-title":"N Engl J Med"},{"key":"BF03022259_CR17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1172\/JCI116987","volume":"93","author":"GP Visentin","year":"1994","unstructured":"Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia \/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81\u20138.","journal-title":"J Clin Invest"},{"key":"BF03022259_CR18","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1055\/s-0037-1615969","volume":"85","author":"M Khairy","year":"2001","unstructured":"Khairy M, Lasne D, Brohard-Bohn B, Aiach M, Rendu F, Bachelot-Loza C. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb Haemost 2001; 85: 1090\u20136.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR19","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1182\/blood.V97.10.3300","volume":"97","author":"C Pouplard","year":"2001","unstructured":"Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparininduced thrombocytopenia. Blood 2001; 97: 3300\u20132.","journal-title":"Blood"},{"key":"BF03022259_CR20","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.V98.8.2442","volume":"98","author":"MP Reilly","year":"2001","unstructured":"Reilly MP, Taylor SM, Hartman NK, et al. Heparininduced thrombocytopenia\/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 2001; 98: 2442\u20137.","journal-title":"Blood"},{"key":"BF03022259_CR21","first-page":"189","volume-title":"Heparin-Induced Thrombocytopenia","author":"G Denomme","year":"2001","unstructured":"Denomme G. The platelet Fc receptor in heparininduced thrombocytopenia.In:Greinacher A (Ed.). Heparin-Induced Thrombocytopenia, 2nd ed. NewYork-Basel: Marce Dekker, Inc; 2001: 189\u2013214.","edition":"2nd ed."},{"key":"BF03022259_CR22","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2004-01-0058","volume":"104","author":"Y Gruel","year":"2004","unstructured":"Gruel Y, Pouplard C, Lasne D, Magdelaine-Beuzelin C, Charroing C, Watier H. The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 2004; 104: 2791\u20133.","journal-title":"Blood"},{"key":"BF03022259_CR23","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2003.04363.x","volume":"121","author":"Y Gruel","year":"2003","unstructured":"Gruel Y, Pouplard C, Nguyen P, et al.; French Heparin-Induced Thrombocytopenia Study Group. Biological and clinical features of low-molecular-weight heparininduced thrombocytopenia. Br J Haematol 2003; 121: 786\u201392.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00001721-199703000-00005","volume":"8","author":"J Amiral","year":"1997","unstructured":"Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A\/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 114\u20137.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"BF03022259_CR25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2004-05-2010","volume":"105","author":"P Savi","year":"2005","unstructured":"Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 139\u201344.","journal-title":"Blood"},{"key":"BF03022259_CR26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009","volume":"129","author":"JN George","year":"1998","unstructured":"George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129: 886\u201390.","journal-title":"Ann Intern Med"},{"key":"BF03022259_CR27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1378\/chest.115.5.1363","volume":"115","author":"F Stephan","year":"1999","unstructured":"Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest 1999; 115: 1363\u201370.","journal-title":"Chest"},{"issue":"3","key":"BF03022259_CR28","doi-asserted-by":"crossref","first-page":"311S","DOI":"10.1378\/chest.126.3_suppl.311S","volume":"126","author":"TE Warkentin","year":"2004","unstructured":"Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 311S-37S.","journal-title":"Chest"},{"key":"BF03022259_CR29","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/s-0038-1642729","volume":"73","author":"H Schrezenmeier","year":"1995","unstructured":"Schrezenmeier H, Muller H, Gunsilius E, Heimpel H, Seifried E. Anticoagulant-induced pseudothrombocytopenia and pseudoleucocytosis. Thromb Haemost 1995; 73: 506\u201313.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","volume":"344","author":"TE Warkentin","year":"2001","unstructured":"Warkentin TE, Kelton JG. Temporal aspects of heparininduced thrombocytopenia. N Engl J Med 2001; 344: 1286\u201392.","journal-title":"N Engl J Med"},{"key":"BF03022259_CR31","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2002-07-2201","volume":"101","author":"B Girolami","year":"2003","unstructured":"Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101: 2955\u20139.","journal-title":"Blood"},{"key":"BF03022259_CR32","first-page":"409","volume":"136","author":"GR Rhodes","year":"1973","unstructured":"Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973; 136: 409\u201316.","journal-title":"Surg Gynecol Obstet"},{"key":"BF03022259_CR33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","volume":"101","author":"TE Warkentin","year":"1996","unstructured":"Warkentin TE, Kelton JG. A 14-year study of heparininduced thrombocytopenia. Am J Med 1996; 101: 502\u20137.","journal-title":"Am J Med"},{"key":"BF03022259_CR34","first-page":"53","volume-title":"Heparin-Induced Thrombocytopenia","author":"T Warkentin","year":"2004","unstructured":"Warkentin T. Clinical picture of heparin-induced thrombocytopenia. In:Greinacher A (Ed.). Heparin-Induced Thrombocytopenia, 2nd ed. New-York-Basel: Marce Dekker, Inc; 2004: 53\u2013106.","edition":"2nd ed."},{"key":"BF03022259_CR35","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1055\/s-0037-1614355","volume":"82","author":"B Tardy","year":"1999","unstructured":"Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, Dacosta A. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999; 82: 1199\u2013200.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-0037-1615866","volume":"82","author":"A Greinacher","year":"1999","unstructured":"Greinacher A. Treatment of heparin-induced thrombocytopenia. Thromb Haemost 1999; 82: 457\u201367.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1365-2141.1996.d01-1481.x","volume":"92","author":"TE Warkentin","year":"1996","unstructured":"Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494\u20137.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0887-7963(96)80001-0","volume":"10","author":"TE Warkentin","year":"1996","unstructured":"Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant\/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996; 10: 249\u201358.","journal-title":"Transfus Med Rev"},{"key":"BF03022259_CR39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0003-4975(03)00756-2","volume":"76","author":"TE Warkentin","year":"2003","unstructured":"Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 638\u201348.","journal-title":"Ann Thorac Surg"},{"key":"BF03022259_CR40","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/archinte.163.20.2518","volume":"163","author":"TE Warkentin","year":"2003","unstructured":"Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518\u201324.","journal-title":"Arch Intern Med"},{"key":"BF03022259_CR41","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1538-7836.2004.00949.x","volume":"2","author":"Louet A Lillo-Le","year":"2004","unstructured":"Lillo-Le Louet A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytope nia after cardiopulmonary bypass. J Thromb Haemost 2004; 2: 1882\u20138.","journal-title":"J Thromb Haemost"},{"key":"BF03022259_CR42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1365-2141.2005.05381.x","volume":"128","author":"C Pouplard","year":"2005","unstructured":"Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128: 837\u201341.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0950-3536(98)80060-7","volume":"11","author":"J Amiral","year":"1998","unstructured":"Amiral J, Meyer D. Heparin-induced thrombocytopenia: diagnostic tests and biological mechanisms. Baillieres Clin Haematol 1998; 11: 447\u201360.","journal-title":"Baillieres Clin Haematol"},{"key":"BF03022259_CR44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1537-2995.1994.34594249047.x","volume":"34","author":"A Greinacher","year":"1994","unstructured":"Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparinassociated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4\/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381\u20135.","journal-title":"Transfusion"},{"key":"BF03022259_CR45","first-page":"371","volume":"120","author":"TE Warkentin","year":"1992","unstructured":"Warkentin TE, Hayward CP, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 371\u20139.","journal-title":"J Lab Clin Med"},{"key":"BF03022259_CR46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.1986.tb07582.x","volume":"64","author":"SL Pfueller","year":"1986","unstructured":"Pfueller SL, David R. Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia. Br J Haematol 1986; 64: 149\u201359.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","volume":"67","author":"D Sheridan","year":"1986","unstructured":"Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27\u201330.","journal-title":"Blood"},{"key":"BF03022259_CR48","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1055\/s-0038-1646493","volume":"66","author":"A Greinacher","year":"1991","unstructured":"Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associ-ated thrombocytopenia. Thromb Haemost 1991; 66: 734\u20136.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR49","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1365-2141.1997.2613077.x","volume":"98","author":"A Tomer","year":"1997","unstructured":"Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997; 98: 648\u201356.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/s-0037-1614938","volume":"79","author":"C Bachelot-Loza","year":"1998","unstructured":"Bachelot-Loza C, Saffroy R, Lasne D, Chatellier G, Aiach M, Rendu F. Importance of the FcgammaRIIa-Arg\/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998; 79: 523\u20138.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1067\/mlc.2001.115525","volume":"138","author":"GP Visentin","year":"2001","unstructured":"Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombo-cytopenia\/thrombosis. J Lab Clin Med 2001; 138: 22\u201331.","journal-title":"J Lab Clin Med"},{"key":"BF03022259_CR52","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2002-02-0620","volume":"101","author":"V Regnault","year":"2003","unstructured":"Regnault V, de Maistre E, Carteaux JP, et al. Platelet activation induced by human antibodies to interleukin-8. Blood 2003; 101: 1419\u201321.","journal-title":"Blood"},{"key":"BF03022259_CR53","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1046\/j.1538-7836.2003.00282.x","volume":"1","author":"A Fohlen-Walter","year":"2003","unstructured":"Fohlen-Walter A, De Maistre E, Mulot A, Marchand-Arvier M, Lecompte T. Does negative heparin-platelet factor 4 enzyme-linked immunosorbent assay effectively exclude heparin-induced thrombocytopenia? J Thromb Haemost 2003; 1: 1844\u20135.","journal-title":"J Thromb Haemost"},{"key":"BF03022259_CR54","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2141.1998.00750.x","volume":"101","author":"M Trossaert","year":"1998","unstructured":"Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin\/ platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998; 101: 653\u20135.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR55","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.CIR.95.5.1242","volume":"95","author":"TL Bauer","year":"1997","unstructured":"Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242\u20136.","journal-title":"Circulation"},{"key":"BF03022259_CR56","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.0007-1048.2002.03363.x","volume":"116","author":"P Eichler","year":"2002","unstructured":"Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A. The new ID-heparin\/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002; 116: 887\u201391.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR57","first-page":"148","volume":"2","author":"TE Warkentin","year":"2003","unstructured":"Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148\u201357.","journal-title":"Curr Hematol Rep"},{"key":"BF03022259_CR58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-04-1089","volume":"101","author":"BM Alving","year":"2003","unstructured":"Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood. 2003; 101: 31\u20137.","journal-title":"Blood."},{"key":"BF03022259_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0037-1614206","volume":"79","author":"TE Warkentin","year":"1998","unstructured":"Warkentin TE, Chong BH, Greinacher A. Heparininduced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1\u20137.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR60","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1046\/j.1538-7836.2003.00270.x","volume":"1","author":"BH Chong","year":"2003","unstructured":"Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471\u20138.","journal-title":"J Thromb Haemost"},{"key":"BF03022259_CR61","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood-2002-04-1055","volume":"101","author":"A Greinacher","year":"2003","unstructured":"Greinacher A, Eichler P, Albrecht D, Strobel U, Potzsch B, Eriksson BI. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003; 101: 2617\u20139.","journal-title":"Blood"},{"key":"BF03022259_CR62","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","volume":"103","author":"BE Lewis","year":"2001","unstructured":"Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838\u201343.","journal-title":"Circulation"},{"key":"BF03022259_CR63","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","volume":"163","author":"BE Lewis","year":"2003","unstructured":"Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849\u201356.","journal-title":"Arch Intern Med"},{"key":"BF03022259_CR64","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0037-1615946","volume":"85","author":"B Farner","year":"2001","unstructured":"Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 950\u20137.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR65","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1378\/chest.115.6.1616","volume":"115","author":"B Tardy-Poncet","year":"1999","unstructured":"Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999; 115: 1616\u201320.","journal-title":"Chest"},{"key":"BF03022259_CR66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.1999.01532.x","volume":"106","author":"G Huhle","year":"1999","unstructured":"Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999; 106: 195\u2013201.","journal-title":"Br J Haematol"},{"key":"BF03022259_CR67","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.V96.7.2373","volume":"96","author":"P Eichler","year":"2000","unstructured":"Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin- induced thrombocytopenia treated with lepirudin: inci- dence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373\u20138.","journal-title":"Blood"},{"key":"BF03022259_CR68","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00003495-199754060-00008","volume":"54","author":"MI Wilde","year":"1997","unstructured":"Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54: 903\u201324.","journal-title":"Drugs"},{"key":"BF03022259_CR69","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/01.CIR.103.10.1479","volume":"103","author":"A Greinacher","year":"2001","unstructured":"Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001; 103: 1479\u201384.","journal-title":"Circulation"},{"key":"BF03022259_CR70","doi-asserted-by":"crossref","first-page":"344S","DOI":"10.1378\/chest.119.1_suppl.344S","volume":"119","author":"P Monagle","year":"2001","unstructured":"Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001; 119: 344S-70S.","journal-title":"Chest"},{"issue":"1","key":"BF03022259_CR71","first-page":"920","volume":"77","author":"B Potzsch","year":"1997","unstructured":"Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77(1 Suppl): 920\u20135.","journal-title":"Thromb Haemost"},{"key":"BF03022259_CR72","first-page":"429","volume-title":"Heparin-Induced Thrombocytopenia","author":"B Poetzsch","year":"2001","unstructured":"Poetzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In:Greinacher A (Ed.). Heparin-Induced Thrombocytopenia, 2nd ed. NewYork-Basel: Marce Dekker, Inc.; 2001: 429\u201344.","edition":"2nd ed."},{"key":"BF03022259_CR73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF03018923","volume":"47","author":"D Longrois","year":"2000","unstructured":"Longrois D, de Maistre E, Bischoff N, et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anesth 2000; 47: 255\u201360.","journal-title":"Can J Anesth"},{"key":"BF03022259_CR74","first-page":"265","volume":"91","author":"A Koster","year":"2000","unstructured":"Koster A, Merkle F, Hansen R, et al. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 2000; 91: 265\u20139.","journal-title":"Anesth Analg"},{"key":"BF03022259_CR75","first-page":"487","volume-title":"New Anticoagulants for the Cardiovascular Patient","author":"H Magnani","year":"1997","unstructured":"Magnani H, Beijering R, Ten Cate J, Chong B. Oragrananticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.In:Pifarre R (Ed.). New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley and Belfus; 1997: 487\u2013500."},{"key":"BF03022259_CR76","first-page":"354","volume":"5","author":"T Antoniou","year":"2002","unstructured":"Antoniou T, Kapetanakis EI, Theodoraki K, et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum 2002; 5: 354\u20137.","journal-title":"Heart Surg Forum"},{"key":"BF03022259_CR77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00000542-200102000-00013","volume":"94","author":"A Koster","year":"2001","unstructured":"Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001; 94: 245\u201351.","journal-title":"Anesthesiology"}],"container-title":["Canadian Journal of Anesthesia\/Journal canadien d'anesth\u00e9sie"],"original-title":[],"language":"fr","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03022259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03022259\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03022259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T22:00:12Z","timestamp":1589752812000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03022259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":77,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["BF03022259"],"URL":"https:\/\/doi.org\/10.1007\/bf03022259","relation":{},"ISSN":["0832-610X","1496-8975"],"issn-type":[{"value":"0832-610X","type":"print"},{"value":"1496-8975","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}